pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update
The February 28, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are:
- Seven new drug products have initiated pCPA negotiations, for a total of 39 active negotiations;
- Five negotiations have been completed/closed, for a total of 205 joint completed/closed negotiations; and
- No new drug products were added to the “No pCPA Negotiations” list, for a total of 57 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level.
Negotiation Initiation
- Seven new drug products have initiated pCPA negotiations since the last update, for a total of 39 active negotiations
| Brand Name | Generic Name | Manufacturer | Indication | Recommendation/ Notification to Implement Date |
Time to Initiation* |
|---|---|---|---|---|---|
| Actikerall | Fluorouracil and Salicylic Acid | Cipher Pharmaceuticals Inc. | Hyperkeratotic actinic keratosis | March 22, 2017 | 330 days |
| Jevtana | Cabazitaxel | Sanofi Genzyme | castration resistant metastatic prostate cancer | N/A | N/A |
| Procysbi | Cysteamine bitartrate | Horizon Therapeutics Canada | Nephropathic cystinosis | January 24, 2018 | 22 days |
| Rosiver** | Ivermectin | Galderma Canada Inc. | Rosacea | November 19, 2015 | 819 days |
| Rydapt | Midostaurin | Novartis Pharmaceuticals Canada Inc. | Acute myeloid leukemia (AML) | January 11, 2018 | 35 days |
| Stelara | Ustekinumab | Janssen Inc. | Crohn’s Disease | March 21, 2017 | 331 days |
| Vosevi | Sofosbuvir velpatasvir voxilaprevir | Gilead Sciences Canada | Chronic hepatitis C | January 23, 2018 | 23 days |
*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation
** This is the 2nd negotiation for Rosiver, the first was closed in August 2016.
Signals Decoded:
The list of negotiations initiated in February include a wide variety of characteristics:
• 3 files initiated quickly: Rydapt (for AML), Procysbi (for nephropathic cystinosis where access to the current standard of care through Health Canada’s Special Access Program appears to be changing), and Vosevi (for treatment of Hepatitis C);
• 2 files initiated after being under pCPA consideration for 11 months: Actikerall (for hyperkeratotic actinic keratosis) and Stelara (for Crohn’s disease);
• 1 file re-initiated after previous negotiation closure without a LOI: Rosiver (for rosacea); and
• 1 file initiated without a new HTA recommendation: Jevtana (for prostate cancer)
*Files under pCPA Consideration are based on data collected by MORSE Consulting
Negotiations Completed
- Five negotiations have been completed/closed since the last update, for a total of 205 joint completed/closed negotiations.
- Four negotiations were completed:
| Brand Name | Generic Name | Manufacturer | Indication | Negotiation Initiation | Duration * |
|---|---|---|---|---|---|
| Botox | Onabotulinomtoxin A | Allergan Inc. | Multiple indications | December, 2016 | 427 days |
| Invega Trinza | Paliperidone palmitate | Janssen-Ortho Inc. | Schizophrenia | May, 2017 | 276 days |
| Mictoryl | Propiverine | Duchesnay Inc. | Overactive bladder (paediatric) | August, 2017 | 184 days |
| Vosevi | Sofosbuvir velpatasvir voxilaprevir | Gilead Sciences Canada | Chronic hepatitis C | February, 2018 | 0 days |
-
- One negotiation was closed
| Brand Name | Generic Name | Manufacturer | Indication | Negotiation Initiation | Duration * |
|---|---|---|---|---|---|
| Mictoryl | Propiverine | Duchesnay Inc. | Overactive bladder | August, 2017 | 184 days |
Signals Decoded:
The negotiation for Vosevi (hepatitis C) was opened and completed within the same month, perhaps due to the success of previous negotiations within the hepatitis C category and with the same manufacturer.
Notably, Mictoryl (for overactive bladder) secured a LOI for only part of its indication, within the pediatric population.
No pCPA Negotiation
- No new drug products were added to the “No pCPA Negotiations” list, for a total of 57 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level
In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. Based on information collected by MORSE Consulting, the latest update since January 31, 2018 is:
- Five new drug products received a CDEC or pERC recommendation or notification to implement since the last update, for a total of approximately 27 products under pCPA Consideration.
| Brand Name |
Generic Name |
Manufacturer |
Indication |
Final Recommendation/ Notification to Implement |
|---|---|---|---|---|
| Orfadin | Nitisinone | Sobi Canada Inc. | Hereditary tyrosinernia type 1 | Conditional Reimbursement |
| Tremfya | Guselkumab | Janssen Inc. | Psoriasis, moderate to severe plaque | Conditional Reimbursement |
| Renflexis | Infliximab | Merck Canada Inc. | Rheumatoid arthritis
Ankylosing spondylitis Adult Crohn’s Disease Pediatric Crohn’s Disease Fistulizing Crohn’s Disease Adult Ulcerative Colitis Pediatric Ulcerative Colitis Psoriatic Arthritis Plaque Psoriasis |
Conditional Reimbursement |
| Faslodex | Fulvestrant | AstraZeneca Canada Inc. | Locally advanced or metastatic breast cancer | Conditional Reimbursement |
| Adcetris | Brentuximab vedotin | Seattle Genetics Inc. | Hodgkin’s lymphoma at high risk of relapse or progression post-ASCT | Conditional Reimbursement |
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
